People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Endeavor Biomedicines, Inc. | — | Biotechnology | Series D+ | $221.7M | $1.6B | 2024 |
Karan Cheong Takhar at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Karan Cheong Takhar on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick G. Enright | 1 | 7 |
| BERNARD DAVITIAN | 1 | 4 |
| Miguel De Los Rios | 1 | 3 |
| Chris Krueger | 1 | 3 |
| Vishaal Turakhia | 1 | 1 |
| Raghu Saripalli | 1 | 1 |
| Enoch Kariuki | 1 | 1 |
| Monal Cheong Mehta | 1 | 1 |
| Wing Cheong Lam | 1 | 1 |
| John Hood | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.